Nilotinib plus multi-agent chemotherapy for philadelphia chromosome-positive acute lymphoblastic leukemia.
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2016
At a glance
- Drugs Nilotinib (Primary) ; Antineoplastics
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Novartis
- 19 Dec 2011 Status changed from not yet recruiting to recruiting as reported by Chinese Clinical Trial Register.
- 11 Jun 2010 New trial record